title: Hypereosinophilia due to mesalazine treatment.
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Usta
authors.forename: Hasan
authors.initials: H
authors.lastname: Ozen
authors.forename: Figen
authors.initials: F
authors.lastname: Gurakan
authors.forename: Nuray
authors.initials: N
authors.lastname: Uslu
authors.forename: Inci Nur
authors.initials: IN
authors.lastname: Saltik-Temizel
authors.forename: Hulya
authors.initials: H
authors.lastname: Demir
authors.forename: Aysel
authors.initials: A
authors.lastname: Yuce
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000139:chemically induced*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D008297:Male; D019804:Mesalamine / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine